Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 9/20 | 0.77 |
| ▸ | TACR2 | P21452 | 8/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.77 |
| ▸ | TRPV4 | Q9HBA0 | 12/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732536 | 0.92 | TACR2 (0.71) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL6507791 | 0.89 | TACR3 (0.62) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL2373330 | 0.87 | TRPV4 (0.72) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL5945344 | 0.87 | TRPV4 (0.80) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL7225413 | 0.87 | TRPV4 (0.67) | TACR3TACR2OPRM1TRPV4 | |
| Hydrochloric Acid SCHEMBL5733490 | 0.86 | TRPV4 (0.71) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL5203642 | 0.86 | TRPV4 (0.73) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL6428018 | 0.85 | TRPV4 (0.70) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL5734797 | 0.84 | TACR2 (1.00) | TACR3TACR2OPRM1TRPV4KCNH2 | |
| SCHEMBL2514030 | 0.84 | TRPV4 (0.81) | TACR3TACR2OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060161004-A1 | Novel compounds | GLAXOSMITHKLINE SPA | 2006-07-20 | — | — | US | disclosed |
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| US-20040102633-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | TACR3 301/4885TACR2 52/4885OPRM1 40/4885 |
| US-20060161004-A1 | Novel compounds | SLC10A1, ABCB11, AQP1 | TACR3 2824/4885TACR2 862/4885OPRM1 2549/4885 |
| US-20040102633-A1 | Novel compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 | TACR3 1027/4885TACR2 155/4885OPRM1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.